This autologous vaccine modifies patient’s dendritic cells (DC) ex-vivo, resulting in the expression of a recombinant fusion protein of prostatic acid phosphatase (PAP), a prostate-cancer specific antigen, with granulocyte macrophage colony-stimulating factor (GM-CSF), an immune stimulatory protein. The gene discussed is CSF2; the disease is prostate cancer.